Publications by authors named "Ducep J"

The first successful preparation of mono- and disubstituted 3,7-dihydroxytropolone involves a four-step synthetic scheme. Thus, bromination of 3,7-dihydroxytropolone (8) followed by permethylation of the resultant products furnished gram quantities of intermediates 13-18. Single or double Suzuki coupling reactions between these permethylated monobromo- and dibromodihydroxytropolone derivatives and a variety of boronic acids delivered the expected products whose deprotection yielded the desired compounds 1a-u and 26a-n, usually in fair to good yields.

View Article and Find Full Text PDF

The total syntheses of the 5- and 6-fluoro derivatives of 5,8,14-eicosatrienoic (ETA) and arachidonic (AA) acids are described. The fluorinated double bond was introduced using (E)-1,4-dihydroxy-2-fluoro-2-butene obtained through diisobutylaluminium hydride reduction of dimethylfluoromaleate. Recently, 5-fluoro and 6-fluoro arachidonic acids (5-F-AA and 6-F-AA) were found to be effective inhibitors of 5-lipoxygenase in vitro (Nave, J.

View Article and Find Full Text PDF

The 5- and 6-fluoro derivatives of arachidonic acid (5F-ETE and 6F-ETE) were evaluated as substrates of rat basophilic leukaemia cell (RBL-1) 5-lipoxygenase. 5F-ETE was found to be a poor substrate and was converted into a single product, 5-oxoeicosa-6,8,11,14-tetraenoic acid (5-oxo-ETE). 6F-ETE was a good substrate and was mainly converted into 5-hydroperoxy-6-fluoroeicosa-6,8,11,14-tetraenoic acid (5-OOH-6F-ETE) with concomitant formation of a small amount of 5-oxo-6-fluoroeicosa-6,8,11,14-tetraenoic acid (5-oxo-6F-ETE).

View Article and Find Full Text PDF

Inhibition of intestinal alpha-glucohydrolase activity is one approach for reducing the glycemic response from dietary carbohydrate and may prove useful for the treatment of diabetes mellitus. In this article, we describe the pharmacological properties of a time-dependent intestinal alpha-glucohydrolase inhibitor, MDL 73945. When preincubated 2 h with a rat intestinal mucosa preparation before substrate addition, MDL 73945 was a potent inhibitor of sucrase, maltase, glucoamylase, and isomaltase activities (MDL 73945 concentrations required to cause a 50% decrease in enzyme activity, 2 x 10(-7), 1 x 10(-6), 5 x 10(-6), and 8 x 10(-6) M, respectively); without preincubation, it was 10- to 500-fold less potent.

View Article and Find Full Text PDF

2-(4-Amino-4-carboxybutyl)aziridine-2-carboxylic acid (3) (aziridino-DAP) was identified as the product of spontaneous hydrolysis of alpha-(halomethyl)diaminopimelic acids (alpha-halomethyl-DAPs) 2a-c. Under physiological conditions, 3 is an extremely potent irreversible inhibitor of the bacterial enzyme diaminopimelic acid epimerase (DAP-epimerase; EC 5.1.

View Article and Find Full Text PDF

5,8,14-eicosatrienoic (5,8,14-ETA) and 5,8-eicosadienoic (5,8-EDA) acids are converted by the 5-lipoxygenase from RBL-1 cells into 5-hydroperoxy-6,8,14-eicosatrienoic (5-OOH-ETA) and 5-hydroperoxy-6,8-eicosadienoic (5-OOH-EDA) acids, respectively. These hydroperoxy fatty acids, unlike 5-hydroperoxy-6,8,11,14-eicosatetraenoic acid (5-HPETE), are not further processed into leukotrienes by the leukotriene A4 synthase activity of 5-lipoxygenase. 5,8,14-ETA was used to establish the saturation kinetics of 5-lipoxygenase in the 100,000g supernatant from RBL-1 cells.

View Article and Find Full Text PDF

myo-Inositol-1-phosphatase from bovine brain was purified over 2000-fold. The native enzyme has a Mr of 59,000, and on SDS/polyacrylamide-gel electrophoresis the subunit Mr was 31,000. Thus the native enzyme is a dimer of two apparently identical subunits.

View Article and Find Full Text PDF

6-Fluoromevalonate blocks the incorporation of mevalonic acid, but not that of isopentenyl pyrophosphate, into non-saponifiable lipids in a rat liver multienzyme system. With 3H-labelled 6-fluoromevalonate, it was found that 6-fluoromevalonate is converted to its phospho and pyrophospho derivatives in this system. The kinetics of the two kinases were studied.

View Article and Find Full Text PDF

14-diethoxyacetoxy daunorubicin (R.P. 33 921) was chosen among a series of new daunorubicin analogues.

View Article and Find Full Text PDF